dc.creatorUrquiza, Nora M.
dc.creatorManca, Silvia G.
dc.creatorMoyano, María Alejandra
dc.creatorDellmans, Raquel Arrieta
dc.creatorLezama, Luis
dc.creatorRojo, Teófilo
dc.creatorNaso, Luciana Gissella
dc.creatorWilliams, Patricia Ana María
dc.creatorFerrer, Evelina Gloria
dc.date2009-12-11
dc.date2022-03-23T12:43:20Z
dc.date.accessioned2023-07-15T04:38:11Z
dc.date.available2023-07-15T04:38:11Z
dc.identifierhttp://sedici.unlp.edu.ar/handle/10915/133155
dc.identifierissn:1572-8773
dc.identifierissn:0966-0844
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/7470309
dc.descriptionMethimazole (MeimzH<b>)</b> is an anti-thyroid drug and the first choice for patients with Grave’s disease. Two new copper(II) complexes of this drug: [Cu(MeimzH)<sub>2</sub>(NO<sub>3</sub>)<sub>2</sub>].0.5H<sub>2</sub>O and [Cu(MeimzH)<sub>2</sub>(H<sub>2</sub>O)<sub>2</sub>](NO<sub>3</sub>)<sub>2</sub>·H<sub>2</sub>O were synthesized and characterized by elemental analysis, dissolution behavior, thermogravimetric analysis and UV-vis, diffuse reflectance, FTIR and EPR spectroscopies. As it is known that copper(II) cation can act as an inhibitor of alkaline phosphatase (ALP), the inhibitory effect of methimazole and its copper(II) complexes on ALP activity has also been investigated.
dc.descriptionCentro de Química Inorgánica
dc.formatapplication/pdf
dc.format255-264
dc.languageen
dc.rightshttp://creativecommons.org/licenses/by/4.0/
dc.rightsCreative Commons Attribution 4.0 International (CC BY 4.0)
dc.subjectQuímica
dc.subjectMethimazole
dc.subjectCopper
dc.subjectBiometals
dc.subjectGrave’s disease
dc.subjectEPR
dc.subjectFTIR
dc.subjectUV-visible
dc.subjectALP inhibition
dc.titleCopper(II) complexes of methimazole, an anti Grave’s disease drug : Synthesis, characterization and its potential biological behavior as alkaline phosphatase inhibitor
dc.typeArticulo
dc.typeArticulo


Este ítem pertenece a la siguiente institución